Search Results

Nicoya®, a pioneering life science instrument company specializing in innovative biosensor technology, is pleased to announce the appointment of Medispec as its exclusive distributor in India.

Nicoya Lifesciences, a global innovator of digital proteomics solutions for diagnostics and biotherapeutic discovery, today announced the acquisition of LSK Technologies, a University of Toronto startup decentralizing laboratory testing with their high-throughput lab-in-a-box platform.

OPKO Health, Inc. (NASDAQ: OPK) today announced that its subsidiary EirGen Pharma has entered into an agreement with Nicoya Macau Limited, an affiliate of Nicoya Therapeutics (Nicoya), for the development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan) of RAYALDEE ® for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD).

Nicoya Lifesciences, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, is pleased to announce that it is receiving additional advisory services and funding to continue research and development of its rapid, saliva-based COVID-19 antigen test

Nicoya, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, will receive advisory services and up to $299,190 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRA

The funding will enable Nicoya to expedite the development of new products focused on drug discovery, grow its team from 50 employees to 80 over the next year, expand its reach to more international markets, and target new opportunities within the biotechnology and pharmaceutical industries.

Groundbreaking new SPR system uses digital microfluidics technology and flexible 16-channel design to reduce the time and cost of drug discovery